Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials
China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...
Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...
Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...
Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights
Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...
Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy
China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...
MicroPort CardioFlow’s AnchorMan LAA Occluder System Earns CE Mark Approval
Hong Kong-listed MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has received the CE mark for...
AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design
China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the...
Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...
AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments
The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent...
In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications
The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on...
State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms
The State Council has released a second draft proposal outlining measures to support the high-quality...
Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing...
Shanghai Issues Legal Guidebook for Innovative Drug Marketing
The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...
China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation
The Chinese government has released a set of opinions detailing the establishment of a new...
Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co.,...
GSK’s Nucala Receives NMPA Review for COPD Treatment
GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has...
Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE
According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...